BR0001602A - Composto de aminotriazol, processo para a preparação dos mesmos e composições farmacêuticas contendo os mesmos - Google Patents

Composto de aminotriazol, processo para a preparação dos mesmos e composições farmacêuticas contendo os mesmos

Info

Publication number
BR0001602A
BR0001602A BR0001602-0A BR0001602A BR0001602A BR 0001602 A BR0001602 A BR 0001602A BR 0001602 A BR0001602 A BR 0001602A BR 0001602 A BR0001602 A BR 0001602A
Authority
BR
Brazil
Prior art keywords
heteroarylalkyl
group
optionally substituted
pharmaceutical compositions
compositions containing
Prior art date
Application number
BR0001602-0A
Other languages
English (en)
Inventor
Jean-Luc Fauchere
Jean-Claude Ortuno
Jacques Duhault
Jean Albert Boutin
Nigel Levens
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Publication of BR0001602A publication Critical patent/BR0001602A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: <B>"COMPOSTOS DE AMINOTRIAZOL, PROCESSO PARA A PREPARAçãO DOS MESMOS E COMPOSIçõES FARMACêUTICAS CONTENDO OS MESMOS"<D>. O composto da fórmula (I): em que: n é 0 ou 1, W representa -CO- ou S(O)~ q~ e q é 0, 1 ou 2, G representa um grupo G~ 1~, G~ 2~, G~ 3~ ou G~ 4~ como definidos na descrição, Z representa um grupo alquil, ou um grupo aril, heteroaril, arilalquil, arilalquenil, arilalquinil, heteroarilalquenil, heteroarilalquinil ou heteroarilalquil, cada um substituído opcionalmente, A representa um grupamento selecionado de -A~ 2~-, -A~ 1~<sym>A~ 2~-, -A~ 2~-A~ 1~- e -A~ 1~-A~ 2~-A~ 1~- em que A~ 1~ é um grupo alquileno e A~ 2~ representa um grupo fenileno, cicloalquileno, naftileno ou heteroarileno, cada um substituído opcionalmente, R representa um átomo de hidrogênio, um grupo alquil ou um grupo aril, heteroaril, arilalquil, arilalquenil, arilalquinil, heteroarilalquenil, heteroarilalquinil ou heteroarilalquil, cada um substituído opcionalmente, R~ 1~ representa um grupo alquil ou um grupo aril, heteroaril, arilalquil, arilalquenil, arilalquinil, heteroarilalquenil, heteroarilalquinil ou heteroarilalquil, cada um substituído opcionalmente.
BR0001602-0A 1999-04-15 2000-04-13 Composto de aminotriazol, processo para a preparação dos mesmos e composições farmacêuticas contendo os mesmos BR0001602A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9904721A FR2792314B1 (fr) 1999-04-15 1999-04-15 Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
BR0001602A true BR0001602A (pt) 2001-08-21

Family

ID=9544433

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0001602-0A BR0001602A (pt) 1999-04-15 2000-04-13 Composto de aminotriazol, processo para a preparação dos mesmos e composições farmacêuticas contendo os mesmos

Country Status (19)

Country Link
US (2) US6245916B1 (pt)
EP (1) EP1044970B1 (pt)
JP (1) JP2000309579A (pt)
KR (1) KR20010020732A (pt)
CN (1) CN1145616C (pt)
AT (1) ATE231133T1 (pt)
BR (1) BR0001602A (pt)
CA (1) CA2305940A1 (pt)
DE (1) DE60001190T2 (pt)
DK (1) DK1044970T3 (pt)
EA (1) EA003023B1 (pt)
ES (1) ES2190396T3 (pt)
FR (1) FR2792314B1 (pt)
HU (1) HUP0001562A3 (pt)
NO (1) NO20001964L (pt)
NZ (1) NZ504023A (pt)
PL (1) PL339690A1 (pt)
SI (1) SI1044970T1 (pt)
ZA (1) ZA200001908B (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040254153A1 (en) * 1999-11-08 2004-12-16 Pfizer Inc Compounds for the treatment of female sexual dysfunction
EP1381360A4 (en) * 2001-03-29 2009-12-02 Smithkline Beecham Corp COMPOUNDS AND METHODS FOR INHIBITING METAP2 IN MAMMALS
MXPA02010231A (es) * 2001-11-27 2004-12-13 Warner Lambert Co Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
US7456176B2 (en) 2004-04-08 2008-11-25 Targegen, Inc. Benzotriazine inhibitors of kinases
MX2007002208A (es) * 2004-08-25 2007-05-08 Targegen Inc Compuestos hetrociclicos y metodos de uso.
BRPI0515478A (pt) * 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seu uso como mediadores de estearoil-coa-desaturase
CN101083982A (zh) 2004-09-20 2007-12-05 泽农医药公司 用于治疗硬脂酰CoA去饱和酶介导的疾病的杂环衍生物
TW200626154A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
WO2006034279A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
CN101083986A (zh) * 2004-09-20 2007-12-05 泽农医药公司 双环杂环衍生物及其作为硬脂酰CoA去饱和酶(SCD)抑制剂的用途
TW200626155A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
CN101084207A (zh) * 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
AU2005329423A1 (en) * 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
AR051095A1 (es) * 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso comoinhibidores de la estearoil-coa desaturasa
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
ATE427759T1 (de) 2004-11-01 2009-04-15 Amylin Pharmaceuticals Inc Behandlung von fettsucht und verbundenen erkrankungen
RU2417985C2 (ru) 2005-05-30 2011-05-10 Баниу Фармасьютикал Ко., Лтд. Новые производные пиперидина
BRPI0611187A2 (pt) * 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
CA2618112A1 (en) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone compound
AU2006282260A1 (en) 2005-08-24 2007-03-01 Msd K.K. Phenylpyridone derivative
EP1939194A4 (en) 2005-09-07 2010-12-08 Banyu Pharma Co Ltd AROMATIC SUBSTITUTED BICYLIC PYRIDONE DERIVATIVE
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
AU2006307046A1 (en) 2005-10-27 2007-05-03 Msd K.K. Novel benzoxathiin derivative
NZ568292A (en) 2005-11-10 2011-08-26 Msd Kk Spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide derivatives
WO2007084542A2 (en) * 2006-01-17 2007-07-26 Barrier Therapeutics, Inc. Treatment of inflammatory disorders with triazole compounds
JO3019B1 (ar) 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
JPWO2008038692A1 (ja) 2006-09-28 2010-01-28 萬有製薬株式会社 ジアリールケチミン誘導体
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
MX2010004177A (es) 2007-10-18 2010-05-03 Janssen Pharmaceutica Nv 1,2,4-triazoles trisustituidos.
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
US20100323955A1 (en) * 2007-11-14 2010-12-23 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
CA2714617A1 (en) 2008-03-06 2009-09-11 Banyu Pharmaceutical Co., Ltd. Alkylaminopyridine derivative
AR070936A1 (es) 2008-03-19 2010-05-12 Janssen Pharmaceutica Nv 1,2,4 -triazoles trisustituidos
US20110015198A1 (en) 2008-03-28 2011-01-20 Banyu Pharmaceutical Co., Inc. Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
AR071763A1 (es) * 2008-05-09 2010-07-14 Janssen Pharmaceutica Nv Pirazoles trisustituidos, composiciones farmaceuticas que los contienen, y usos de los mismos en el tratamiento de trastornos neurologicos y psiquiatricos
TWI490214B (zh) * 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為vap-1抑制劑之用途
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2319841A1 (en) 2008-07-30 2011-05-11 Msd K.K. (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102271509A (zh) 2008-10-31 2011-12-07 默沙东公司 用于抗糖尿病药的新型环苯并咪唑衍生物
US8775245B2 (en) 2010-02-11 2014-07-08 News America Marketing Properties, Llc Secure coupon distribution
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
TWI518075B (zh) * 2010-10-01 2016-01-21 大正製藥股份有限公司 1,2,4-triazolone derivatives
EP2677869B1 (en) 2011-02-25 2017-11-08 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法
DK3186242T3 (da) 2014-08-29 2021-12-20 Tes Pharma S R L Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
AR109950A1 (es) 2016-10-14 2019-02-06 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
KR20210111248A (ko) 2018-11-20 2021-09-10 테스 파마 에스.알.엘. α-아미노-β-카르복시뮤콘산 세미알데하이드 데카르복실라제의 저해제

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4326465A1 (de) * 1993-01-20 1995-02-09 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JP2000515493A (ja) * 1996-03-29 2000-11-21 ジー.ディー.サール アンド カンパニー パラ―置換フェニレン誘導体
AU7738198A (en) * 1996-12-15 1998-07-15 Banyu Pharmaceutical Co., Ltd. Aminopyrazole derivatives
PE20000127A1 (es) * 1997-12-22 2000-03-14 Novartis Ag Derivado de bencenosulfonamida

Also Published As

Publication number Publication date
CA2305940A1 (fr) 2000-10-15
DE60001190T2 (de) 2003-10-09
HU0001562D0 (en) 2000-06-28
ZA200001908B (en) 2000-10-31
NO20001964L (no) 2000-10-16
US20010018522A1 (en) 2001-08-30
JP2000309579A (ja) 2000-11-07
NO20001964D0 (no) 2000-04-14
US6245916B1 (en) 2001-06-12
SI1044970T1 (en) 2003-06-30
DE60001190D1 (de) 2003-02-20
HUP0001562A2 (hu) 2001-04-28
DK1044970T3 (da) 2003-04-22
NZ504023A (en) 2000-10-27
EA200000327A2 (ru) 2000-10-30
KR20010020732A (ko) 2001-03-15
FR2792314A1 (fr) 2000-10-20
PL339690A1 (en) 2000-10-23
FR2792314B1 (fr) 2001-06-01
EA003023B1 (ru) 2002-12-26
HUP0001562A3 (en) 2003-05-28
CN1272493A (zh) 2000-11-08
CN1145616C (zh) 2004-04-14
ATE231133T1 (de) 2003-02-15
ES2190396T3 (es) 2003-08-01
US6596749B2 (en) 2003-07-22
EP1044970A1 (fr) 2000-10-18
EP1044970B1 (fr) 2003-01-15

Similar Documents

Publication Publication Date Title
BR0001602A (pt) Composto de aminotriazol, processo para a preparação dos mesmos e composições farmacêuticas contendo os mesmos
BR9911013A (pt) Derivados de pirazol como inibidores da p-38 map quinase
HRP20041042A2 (en) Novel substituted sulfamate anticonvulsant derivatives
BR9910474A (pt) Composto derivado de amida, processo para preparação do mesmo, composição farmacêutica, e, uso de um composto derivado de amida
PT813546E (pt) Derivados de polissacarideos contendo ligacoes cruzadas por fotoquimica como suporte para a separacao cromatografica de enantiomeros
BR9913592A (pt) Compostos, processo de preparação dos compostos, e, composições farmacêuticas
BR0115580A (pt) Derivados de 3-aroilindol e a utilizaçao dos mesmos como agonistas dos receptores cb2
PT81855B (pt) Processo de preparacao de arilciclobutilalquilaminas e de composicoes farmaceuticas que as contem
EA200100090A2 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
BR0004823A (pt) Compostos policìclicos de azaindol, processo para a preparação dos mesmos e composições farmacêuticas contendo os mesmos
BR0104471A (pt) Compostos de ciclobutenodiona, um processo para a preparação dos mesmos e composições farmacêuticas que contêm os mesmos
BR9813217A (pt) Tetraciclos, processo para a produção dos mesmos e preparações farmacêuticas contendo estes compostos
BR9907497A (pt) Compostos de imidazolina, um processo para seu preparo e compostos farmacêuticos contendo os mesmos
BR0000158A (pt) Compostos inibidores de reabsorção de ciano-indol serotonina, processo para sua preparação e composições farmacêuticas contendo os mesmos
BR9801448A (pt) Compostos heterocìclicos, processo para sua preparação e composições farmacêuticas contendo os mesmos.
YU37597A (en) New pyranosid derivatives
BR9813712A (pt) Derivados de n-fenilamida e n-piridilamida, método para preparação dos mesmos e composições farmacêuticas contendo os mesmos
BR0213359A (pt) Aralquiltetrahidropiridinas, sua preparação e composições farmacêuticas contendo as mesmas
DE69230446D1 (de) (3s, 4s)-delta-6-tetrahydrocannabinol-7-säuren und ihre derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen
BR9812752A (pt) Derivados de 8-azabiciclo [3.2.1] octano-3-metanamina enquanto ligandos dos receptores de dopamina d2 e d3 e de serotonina 5ht1a e 5ht2
BR9815081A (pt) Compostos tricìclicos, um processo para a sua preparação e composições farmacêuticas contendo-os
ATE8389T1 (de) Amino-alkoxy-pyrazole, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
BRPI0401031A (pt) Compostos de isoquinolina, processo para sua preparação e composições farmacêuticas contendo os mesmos
BR0100600A (pt) Compostos de ácido de aril ou heteroaril quinolinilfosfÈnico, processo para a preparação dos mesmos e composições farmacêuticas contendo os mesmos
BR0001628A (pt) Processo para a preparação de um composto aromático substituìdo por uma nitrila terciária

Legal Events

Date Code Title Description
PC Transfer

Free format text: LES LABORATOIRES SERVIER (FR)

FA10 Dismissal: dismissal - article 33 of industrial property law
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.